首頁 > 市場調查報告書 > 製藥

癌症生物製劑

市場調查報告書

商品編碼

1800187

全球癌症免疫治療市場：2025-2030 年預測

Global Cancer Immunotherapy Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月01日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

癌症免疫治療市場預計將從 2025 年的 1,678.62 億美元成長到 2030 年的 3,412.73 億美元，複合年成長率為 15.25%。

由於癌症發病率的上升以及利用人體免疫系統對抗癌細胞的治療方法的進步，癌症免疫療法市場正在經歷強勁成長。免疫療法利用人體自然防禦機制來辨識和清除癌症，提供一種比傳統療法毒性更低的標靶治療方案。大量的研發投入、先進療法的日益普及以及日益提升的癌症認知度，為該市場的發展提供了支撐。然而，高昂的治療費用和冗長的監管核准流程對市場擴張構成了挑戰。儘管面臨這些挑戰，但預計該市場仍將繼續成長，尤其是在醫療基礎設施完善的地區以及癌症發生率不斷上升的新興國家。

主要成長要素

投資先進免疫療法

癌症免疫療法市場得到了大型製藥企業和研究機構的大力投資。這些投資專注於開發標靶免疫療法，例如查核點抑制劑和CAR-T細胞療法，以增強療效並最大程度地減少副作用。行業領導者之間的合作正在加速新藥開發，以解決癌症治療中尚未滿足的需求並改善患者療效，從而推動市場成長。

肺癌發生率上升

由於吸菸和環境暴露等因素導致肺癌發生率不斷上升，對市場成長貢獻巨大。由於肺癌在世界範圍內發病率高，它在免疫療法市場中佔據了很大佔有率。新興經濟體高昂的醫療支出以及有效治療方法的研發推動了免疫療法的普及，預計將進一步推動對免疫療法的需求，尤其是針對肺癌的特異性治療方法。

The global cancer immunotherapy market is experiencing robust growth, driven by the increasing prevalence of cancer and advancements in therapies that harness the body's immune system to combat cancer cells. Immunotherapy leverages natural defense mechanisms to identify and eliminate cancer, offering targeted treatment options with reduced toxicity compared to traditional methods. The market is propelled by significant investments in research and development, growing adoption of advanced therapies, and rising cancer awareness. However, high treatment costs and lengthy regulatory approval processes pose challenges to market expansion. Despite these hurdles, the market is poised for continued growth, particularly in regions with strong healthcare infrastructure and emerging economies with rising cancer incidences.

Key Growth Drivers

Investments in Advanced Immunotherapies

The cancer immunotherapy market is bolstered by substantial investments from major pharmaceutical companies and research organizations. These investments focus on developing targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, which enhance efficacy and minimize side effects. Collaborative efforts among industry leaders are accelerating the development of novel drugs, driving market growth by addressing unmet needs in cancer treatment and improving patient outcomes.

Rising Incidence of Lung Cancer

The increasing prevalence of lung cancer, driven by factors such as smoking and environmental exposures, significantly contributes to market growth. Lung cancer holds a substantial share of the immunotherapy market due to its high global incidence. The adoption of immunotherapies, supported by high healthcare expenditure in developed economies and ongoing research into effective treatments, is expected to further propel demand, particularly for lung cancer-specific therapies.

Market Segmentation

By Application

The cancer immunotherapy market is segmented into skin cancer, lung cancer, leukemia, bladder cancer, and others. Lung cancer dominates due to its high prevalence and the growing adoption of immunotherapies in regions with strong healthcare systems. Bladder cancer and leukemia also hold significant shares, driven by increased research and development investments targeting these cancer types, which require specialized immunotherapeutic approaches to improve patient outcomes.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. North America is expected to maintain a significant market share, driven by early adoption of innovative therapies, a high prevalence of cancer, and substantial R&D investments. The presence of key market players and a robust regulatory framework, including FDA approvals for immunotherapy drugs, further supports growth. Asia-Pacific is projected to experience rapid growth, fueled by an increasing cancer patient pool, rising awareness, and technological advancements in countries like India and China, where clinical trials for therapies like CAR-T are expanding.

Competitive Landscape

Key players, including Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier, are driving innovation through collaborative research and development of advanced immunotherapies. These companies focus on novel drug combinations and targeted therapies to enhance treatment efficacy and expand market reach.

The cancer immunotherapy market is set for significant growth, propelled by rising cancer incidences, particularly lung cancer, and substantial investments in advanced therapies. North America leads due to its strong healthcare infrastructure, while Asia-Pacific's rapid expansion reflects growing patient needs and clinical advancements. Despite challenges like high costs and regulatory delays, the market's trajectory remains positive, driven by ongoing innovation and the critical role of immunotherapy in transforming cancer treatment.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

The global cancer immunotherapy market has been analyzed through the following segments:

By Type

Monoclonal antibodies (MABs)
Checkpoint Inhibitors
Cytokines
Cancer vaccines
Adoptive Cell Transfer

By Application

Melanoma
Lung Cancer
Leukemias
Bladder Cancer
Breast Cancer
Colorectal Cancer
Others

By End User

Hospitals and Clinics
Cancer Research Centers
Canada

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
Italy
United Kingdom
Others
Middle East and Africa
Israel
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
Australia
South Korea
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE

5.1. Introduction
5.2. Monoclonal antibodies (MABs)
5.3. Checkpoint Inhibitors
5.4. Cytokines
5.5. Cancer vaccines
5.6. Adoptive Cell Transfer

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION

6.1. Introduction
6.2. Melanoma
6.3. Lung Cancer
6.4. Leukemias
6.5. Bladder Cancer
6.6. Breast Cancer
6.7. Colorectal Cancer
6.8. Others

7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER

7.1. Introduction
7.2. Hospitals and Clinics
7.3. Cancer Research Centers

8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. Italy
- 8.4.4. United Kingdom
- 8.4.5. Others
8.5. Middle East & Africa
- 8.5.1. Israel
- 8.5.2. Saudi Arabia
- 8.5.3. UAE
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. South Korea
- 8.6.6. Others